Direct-Acting Antiviral Agents for Hepatitis C Virus Infection

New Protease Inhibitors for the Treatment of Chronic Hepatitis C

(2013) Shan Liu et al.   ANNALS OF INTERNAL MEDICINE

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C

(2012) Calogero Cammà et al.   HEPATOLOGY

Review and management of drug interactions with boceprevir and telaprevir

(2012) Jennifer J. Kiser et al.   HEPATOLOGY

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM

(2011) Femke A.E. Lambers et al.   AIDS

Hepatic Transplant and HCV: A New Playground for an Old Virus

(2011) R. Chinnadurai et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Second-wave Protease Inhibitors: Choosing an Heir

(2011) Sandra Ciesek et al.   Clinics in Liver Disease

The NS5A Replication Complex Inhibitors: Difference Makers?

(2011) Robert G. Gish et al.   Clinics in Liver Disease

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

(2011) Stefan Zeuzem et al.   GASTROENTEROLOGY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations

(2011) I. M. Jacobson et al.   JOURNAL OF VIRAL HEPATITIS

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

(2011) Tarik Asselah et al.   LIVER INTERNATIONAL

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects

(2010) Xiao-Jian Zhou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New NS5B polymerase inhibitors for hepatitis C

(2010) Florence Legrand-Abravanel et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

(2010) L. Rong et al.   Science Translational Medicine

Cellular and molecular biology of HCV infection and hepatitis

(2009) Hengli Tang et al.   CLINICAL SCIENCE

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues

(2009) Nathaniel A Brown   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE